[EN] NAPTHTHALENE DERIVATIVES WHICH INHIBIT THE CYTOKINE OR BIOLOGICAL ACTIVITY OF MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF) [FR] DERIVES DE NAPHTALENE QUI INHIBENT LA CYTOKINE OU L'ACTIVITE BIOLOGIQUE DU FACTEUR INHIBITEUR DE MIGRATION DU MACROPHAGE
[EN] NAPTHTHALENE DERIVATIVES WHICH INHIBIT THE CYTOKINE OR BIOLOGICAL ACTIVITY OF MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF) [FR] DERIVES DE NAPHTALENE QUI INHIBENT LA CYTOKINE OU L'ACTIVITE BIOLOGIQUE DU FACTEUR INHIBITEUR DE MIGRATION DU MACROPHAGE
Napththalene derivatives which inhibit the cytokine or biological activity of microphage migration inhibitory factor (mif)
申请人:Morand Francis Eric
公开号:US20060106102A1
公开(公告)日:2006-05-18
Where Y, R
1
-R
8
and R
101
-R
108
are as defined in the specification. Compounds of formula (II) and methods of inhibiting the cytokine or biological activity of Macrophage Migrating Inhibitory Factor (MIF) comprising contacting MIF with a compound of formula (I) are provided. The invention also relates to methods of treating diseases or conditions where MIF cytokine or biological activity is implicated comprising administration of compounds of formula (1), either alone or as part of a combination therapy.
NAPTHTHALENE DERIVATIVES WHICH INHIBIT THE CYTOKINE OR BIOLOGICAL ACTIVITY OF MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF)
申请人:Cortical Pty Ltd
公开号:EP1549598A1
公开(公告)日:2005-07-06
[EN] NAPTHTHALENE DERIVATIVES WHICH INHIBIT THE CYTOKINE OR BIOLOGICAL ACTIVITY OF MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF)<br/>[FR] DERIVES DE NAPHTALENE QUI INHIBENT LA CYTOKINE OU L'ACTIVITE BIOLOGIQUE DU FACTEUR INHIBITEUR DE MIGRATION DU MACROPHAGE
申请人:CORTICAL PTY LTD
公开号:WO2003104178A1
公开(公告)日:2003-12-18
Where Y, R1-R8 and R101-R108 are as defined
in the specification. Compounds of formula (II) and methods of inhibiting the
cytokine or biological activity of Macrophage Migrating Inhibitory Factor (MIF)
comprising contacting MIF with a compound of formula (I) are provided. The invention
also relates to methods of treating diseases or conditions where MIF cytokine
or biological activity is implicated comprising administration of compounds
of formula (I), either alone or as part of a combination therapy.